Cancer News and Research

Latest Cancer News and Research

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

The rapidly emerging field of precision medicine is a "disruptive innovation" that offers the possibility of remarkably fine-tuned remedies to improve patient health while minimizing the risk of harmful side effects, says J. Larry Jameson, MD, PhD, dean of the Perelman School of Medicine and executive vice president of the University of Pennsylvania for the Health System, in this week's issue of the New England Journal of Medicine.

1 Jun 2015

Modified cold sore (herpes) virus improves survival in stage IIIb to IV melanoma patients

It's a new weapon in the arsenal of cancer fighting treatments: utilizing genetically modified viruses to invade cancer cells and destroy them from the inside.

1 Jun 2015

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Prometheus Laboratories, Inc. announced today the presentation of updated data from the PROCLAIM national patient registry in which first-line Proleukin® (aldesleukin for injection) therapy improved survival in patients with metastatic renal cell carcinoma (mRCC), compared to patients previously treated with targeted therapies.

1 Jun 2015

UN's Global Road Safety Week aims at making roads safer

From 4 to 10 May, the world will be celebrating the UN's Global Road Safety Week under the theme 'Children and road safety', which follows a 10-year series of resolutions aimed at making roads safer.

1 Jun 2015

Strategies needed to optimize communications between police and ED workers

A good working relationship with police is essential for the smooth operation of a busy Emergency Department. Police are in and out of EDs regularly, supporting EMS, transporting patients and helping to provide a safe environment for hospital staff.

1 Jun 2015

FLI invites scientific elite to EKF Symposium on Adult Stem Cells in Aging, Diseases and Cancer

It's already for the fourth time, that Prof. Dr. K. Lenhard Rudolph, scientific director of the Leibniz Institute for Age Research - Fritz Lipmann Institute (FLI) calls the scientific elite of international stem cell researchers to join at Else Kröner Fresenius (EKF) Symposium on Adult Stem Cells in Aging, Diseases and Cancer.

1 Jun 2015

Cancer genetic counselor helps patients make sense of genetics and statistics

Cancer was the second leading cause of death in the United States in 2013 and the American Cancer Society expects almost 10,000 new cases in New Mexico this year.

1 Jun 2015

Post offices selling Aflac cancer products to be expanded throughout Japan

Aflac Incorporated announced today that Japan Post will be expanding the number of post offices selling Aflac cancer products to an additional 10,064 starting July 1, 2015, which will bring the total number of post offices selling Aflac cancer products to 20,076 throughout Japan.

1 Jun 2015

Decipher Prostate Cancer Classifier predicts metastasis in patients treated with salvage radiation therapy

GenomeDx Biosciences today announced that data presented at the 2015 American Society of Clinical Oncology Annual Meeting demonstrate that the Decipher® Prostate Cancer Classifier is a significant predictor of metastasis in patients treated with postoperative salvage radiation therapy.

30 May 2015

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Eisai Inc. announced today the results of its Phase 3 trial (Study 309), which showed that eribulin met the study's primary endpoint evaluating overall survival in patients who had advanced leiomyosarcoma (LMS) or adipocytic sarcoma (ADI), two types of advanced soft tissue sarcoma.

30 May 2015

Palbociclib drug shows promise in women with HR+ metastatic breast cancer

Despite advances in managing and curing some forms of breast cancer, women whose disease becomes metastatic have fewer effective options. A new phase 3 study in some of the most difficult-to-treat patients, women with endocrine-resistant disease, showed that the newly approved drug, palbociclib, more than doubled the time to cancer recurrence for women with hormone-receptor (HR+) positive metastatic breast cancer.

30 May 2015

Removing more tissue during partial mastectomy reduces need for second surgery in breast cancer patients

Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago.

30 May 2015

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

For more than a decade, oncologists using cytotoxic chemotherapy to treat patients with advanced metastatic castration-resistant prostate cancer (mCRPC) have relied on the sequential use of single agent taxanes such as docetaxel and cabazitaxel. For example, docetaxel is commonly used as the "first-line" therapy, while cabazitaxel is used as the "second-line" therapy.

30 May 2015

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Astellas Pharma Inc. today announced that preliminary data from a Phase 1/2 trial on the safety, tolerability and efficacy of ASP2215, a selective inhibitor of FLT3/AXL, in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) were presented during an oral abstract session at the American Society of Clinical Oncology's annual meeting in Chicago.

30 May 2015

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.

30 May 2015

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial.

30 May 2015

ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines

ESMO, the European Society for Medical Oncology, has announced today the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.

30 May 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

CTI BioPharma Corp. and Baxter International's Bioscience business today announced data from PERSIST-1 – a randomized Phase 3 registration-directed trial examining pacritinib for the treatment of myelofibrosis – in a late-breaking oral session at the 51st Annual Meeting of the American Society of Clinical Oncology, May 29-June 2, 2015 in Chicago, Ill.

30 May 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

In a report of a proof-of-principle study of patients with colon and other cancers for whom standard therapies failed, researchers at the Johns Hopkins Kimmel Cancer Center say that mistakes in so-called mismatch repair genes, first identified by Johns Hopkins and other scientists two decades ago, may accurately predict who will respond to certain immunotherapy drugs known as PD-1 inhibitors. Such drugs aim to disarm systems developed by cancer cells to evade detection and destruction by immune system cells.

30 May 2015

Cancer News and Research

Latest Cancer News and Research

Precision medicine helps improve patient health and reduces risk of side effects, says Penn Medical School dean

Modified cold sore (herpes) virus improves survival in stage IIIb to IV melanoma patients

Updated data from PROCLAIM national patient registry presented at 51st ASCO

UN's Global Road Safety Week aims at making roads safer

Strategies needed to optimize communications between police and ED workers

FLI invites scientific elite to EKF Symposium on Adult Stem Cells in Aging, Diseases and Cancer

Cancer genetic counselor helps patients make sense of genetics and statistics

Post offices selling Aflac cancer products to be expanded throughout Japan

Decipher Prostate Cancer Classifier predicts metastasis in patients treated with salvage radiation therapy

Eisai Phase 3 trial of eribulin meets primary endpoint in patients with advanced soft tissue sarcoma

Palbociclib drug shows promise in women with HR+ metastatic breast cancer

Removing more tissue during partial mastectomy reduces need for second surgery in breast cancer patients

New combination chemotherapy may become clinical standard for metastatic castrate-resistant prostate cancer

Preliminary data from ASP2215 Phase 1/2 trial in AML patients presented at ASCO annual meeting

Targeted agent pacritinib significantly reduces burden of advanced myelofibrosis in patients

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Mistakes in mismatch repair genes may accurately predict response to certain immunotherapy drugs

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in